Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$498M |
| 2 |
Micron Technology
MU
|
+$374M |
| 3 |
Amazon
AMZN
|
+$356M |
| 4 |
Accenture
ACN
|
+$318M |
| 5 |
Advanced Micro Devices
AMD
|
+$301M |
Top Sells
| 1 |
Apple
AAPL
|
+$684M |
| 2 |
Meta Platforms (Facebook)
META
|
+$630M |
| 3 |
Tesla
TSLA
|
+$595M |
| 4 |
Chevron
CVX
|
+$497M |
| 5 |
Shopify
SHOP
|
+$439M |
Sector Composition
| 1 | Healthcare | 19.38% |
| 2 | Technology | 18.55% |
| 3 | Consumer Staples | 10.17% |
| 4 | Consumer Discretionary | 9.68% |
| 5 | Financials | 8.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2526
Nurix Therapeutics
NRIX
$652M
| $955K | ﹤0.01% |
73,300
-45,100
| -38% | -$588K |
|
2527
Akebia Therapeutics
AKBA
$780M
| $954K | ﹤0.01% |
3,016,427
+1,534,127
| +103% | +$485K |
|
2528
nLIGHT
LASR
$1.48B
| $954K | ﹤0.01% |
101,000
-28,600
| -22% | -$270K |
|
2529
Cue Biopharma
CUE
$57M
| $950K | ﹤0.01% |
426,147
-153,553
| -26% | -$342K |
|
2530
Sonida Senior Living
SNDA
$503M
| $950K | ﹤0.01% |
58,491
-9,900
| -14% | -$161K |
|
2531
Boston Omaha
BOC
$421M
| $949K | ﹤0.01% |
41,200
-29,900
| -42% | -$689K |
|
2532
Larimar Therapeutics
LRMR
$341M
| $948K | ﹤0.01% |
296,367
+120,825
| +69% | +$386K |
|
2533
Prelude Therapeutics
PRLD
$65.7M
| $948K | ﹤0.01% |
143,400
-17,086
| -11% | -$113K |
|
|
CFB
2534
DELISTED
CrossFirst Bankshares, Inc. Common Stock
CFB
| $945K | ﹤0.01% |
72,400
+500
| +0.7% | +$6.53K |
|
2535
Affinity Bancshares
AFBI
$123M
| $942K | ﹤0.01% |
64,504
-7,900
| -11% | -$115K |
|
2536
Cars.com
CARS
$822M
| $942K | ﹤0.01% |
81,900
+37,000
| +82% | +$426K |
|
2537
Westamerica Bancorp
WABC
$1.22B
| $941K | ﹤0.01% |
18,000
-2,100
| -10% | -$110K |
|
2538
Minerva Neurosciences
NERV
$14.8M
| $940K | ﹤0.01% |
101,800
+66,189
| +186% | +$611K |
|
2539
Vanguard Ultra-Short Bond ETF
VUSB
$5.68B
| $940K | ﹤0.01% |
19,200
-5,900
| -24% | -$289K |
|
2540
Codexis
CDXS
$218M
| $939K | ﹤0.01% |
+154,992
| New | +$939K |
|
2541
Jones Lang LaSalle
JLL
$14.8B
| $937K | ﹤0.01% |
6,200
-11,600
| -65% | -$1.75M |
|
2542
IHS Holding
IHS
$2.39B
| $936K | ﹤0.01% |
167,800
+76,400
| +84% | +$426K |
|
2543
Scholastic
SCHL
$670M
| $935K | ﹤0.01% |
30,401
+2,801
| +10% | +$86.1K |
|
2544
Ingredion
INGR
$7.94B
| $934K | ﹤0.01% |
11,600
-47,500
| -80% | -$3.82M |
|
|
PINE
2545
Alpine Income Property Trust
PINE
$208M
| $926K | ﹤0.01% |
57,078
-55,953
| -50% | -$908K |
|
|
PFHD
2546
DELISTED
Professional Holding Corp. Class A Common stock
PFHD
| $926K | ﹤0.01% |
35,700
+21,000
| +143% | +$545K |
|
2547
DallasNews
DALN
$85.1M
| $924K | ﹤0.01% |
199,051
-21,100
| -10% | -$97.9K |
|
2548
Neurogene
NGNE
$249M
| $923K | ﹤0.01% |
72,103
-8,610
| -11% | -$110K |
|
2549
Citizens
CIA
$271M
| $920K | ﹤0.01% |
275,594
-25,700
| -9% | -$85.8K |
|
2550
Ranpak Holdings
PACK
$391M
| $920K | ﹤0.01% |
269,113
+181,313
| +207% | +$620K |
|